Paradigm Biomedical, Inc is dedicated to the research and development of pharmaceutical products derived from rhamnolipids. Due to recent successful results with our topical application for psoriasis, our focus is to bring this application to market immediately. PBI owns a number of granted and pending patents for internal and topical rhamnolipid applications.  PBI has developed an array of applications for skin disorders such as lichen planus, seborrheic dermatitis, and atopic eczema.  PBI's IP portfolio is world wide and includes specialized  rhamnolipid applications for treating wound healing and burn shock.

PBI is the world leader in developing pharmaceutical products based on rhamnolipids. Rhamnolipid are derived from Pseudomonas Aeruginosa, a natural bacteria found in soil and on plants. Rhamnolipids active properties and low toxicity make them attractive supplements or alternatives to synthetic surfactants used in the pharmaceutical industry, the petroleum industry, agriculture, personal care products, and other applications.

Information on Rhamnolipids